Amgen to Acquire KAI Pharmaceuticals and Gain a Potential Successor to Sensipar®
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 4 (Table of Contents)
Published: 23 Apr-2012
DOI: 10.3833/pdr.v2012.i4.1727 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Amgen has agreed to acquire KAI Pharmaceuticals for US$315 M in cash in order to gain worldwide rights, excluding Japan, to the company’s lead product candidate KAI-4169, a novel peptide agonist that is in Phase II development for secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS